Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TXNRD1 | Q16881 | 16/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089775 | 1.00 | POLB (0.48) | POLBTDP1L3MBTL1TXNRD1MAPT | |
| SCHEMBL26087023 | 0.80 | TXNRD1 (0.42) | POLBTDP1L3MBTL1TXNRD1MAPT | |
| SCHEMBL2689490 | 0.78 | TDP1 (0.52) | POLBTDP1L3MBTL1TXNRD1MAPT | |
| SCHEMBL5753176 | 0.77 | TXNRD1 (0.54) | TXNRD1MAPTMAPK1S1PR4S1PR1 | |
| SCHEMBL26429449 | 0.76 | TXNRD1 (0.37) | POLBTDP1L3MBTL1TXNRD1MAPT | |
| SCHEMBL26429454 | 0.76 | TXNRD1 (0.37) | POLBTDP1L3MBTL1TXNRD1MAPT | |
| SCHEMBL5752857 | 0.76 | ALDH1A1 (0.64) | POLBTDP1TXNRD1MAPTMAPK1 | |
| SCHEMBL2421463 | 0.76 | ALDH1A1 (0.64) | POLBTDP1TXNRD1MAPTMAPK1 | |
| SCHEMBL5754970 | 0.75 | TXNRD1 (0.48) | POLBTDP1L3MBTL1TXNRD1MAPT | |
| SCHEMBL5219253 | 0.75 | TXNRD1 (0.47) | POLBTDP1L3MBTL1TXNRD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | POLB 4490/4885TDP1 2755/4885L3MBTL1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.